University of North Carolina Gillings School of Public Health
Chapel Hill, North Carolina, 27599, United States
NCT Number: NCT02651883
This study will investigate whether cervical cancer screening completion among under-screened women could be improved by offering HPV (human papillomavirus) testing by at-home self-collection followed by screening invitation compared to screening invitation alone.
Looking for future studies?
Notify Me25 year–64 year
Female
Interventional
Not applicable
Chapel Hill, North Carolina, 27599, United States
Invasive cervical cancer (ICC) is preventable through regular screening and treatment, but one fifth of US women report not receiving Pap testing at recommended intervals. More than half of ICC cases occur in these under-screened women. For women 30 years and older, the US Preventive Services Task Force recommends Pap smears alone every 3 years or physician-collected HPV testing with Pap smear (co-testing) every 5 years. The FDA approved primary HPV physician screening for US women 25 years and older. Self-collection for HPV testing is a valid and well-accepted method for detecting HPV infection with comparable sensitivity and specificity to physician-collection for detecting high-grade cervical lesions.
This 2-arm randomized control trial of 510 women will investigate whether offering HPV testing by mailed at-home self-collection to under-screened women increases their likelihood of completing cervical cancer screening. All participants will received a screening invitation by phone: a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free screening at a study-affiliated clinic, if needed. Those randomized to the intervention arm will first be mailed a kit to self-collect a cervico-vaginal sample, return the sample for oncogenic HPV testing, and receive their results by phone. HPV negative women will be considered screening complete. HPV positive women will be invited to schedule an appointment for free follow-up in-clinic screening in the same call in which their results are delivered. The study endpoint of screening completion will be defined as completing in-clinic screening (control arm participants and HPV positive intervention arm participants) or receiving a negative HPV self-collection result (intervention arm).
Aim 1. Determine whether at-home HPV self-collection increases completion of cervical cancer screening among under-screened women offered enhanced reminders.
Aim 2. Examine possible mechanisms explaining the intervention's effect, or lack of an effect.
Aim 3. Estimate the incremental cost per additional woman completing screening of adding at-home HPV self-collection to enhanced reminders.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
Other names: Screening recall, Client reminder
Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
Other names: Self-testing, Self-sampling
Time frame: Six months after enrollment
Completion of cervical cancer screening is defined as (a) testing HPV negative by self-collection, or (b) completing in-clinic screening by i. HPV/Pap co-testing or ii. Pap smear alone.
Time frame: 1-5 weeks after completion of self-collection or screening invitation
Risk appraisal will include multiple components measured by post-intervention questionnaire: Worry; Likelihood; Severity; Embodiment of risk (2 measures); "Gist" risk; Anticipated regret, action; Anticipated regret, inaction
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Incremental cost to payer (public or private) per additional woman screened
Time frame: 1-5 weeks after completion of self-collection or screening invitation
As measured in post-intervention questionnaire
Time frame: 1-5 weeks after completion of self-collection or screening invitation
As measured in post-intervention questionnaire
Time frame: 1-5 weeks after completion of self-collection or screening invitation
Percent of participants that agree to schedule a clinic appointment to get a Pap smear or Pap/HPV co-testing
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
We will assess whether there are differences in the percentage of patients that complete cervical cancer screening by categories of age (e.g., younger than 45 vs. 45+), income, race, and educational level, measures collected at baseline
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Prevalence of HPV infection (as determined by presence of hrHPV mRNA in self- and clinic samples), abnormal cytology (ASCUS+ per NCI Bethesda system), and high-grade lesions (CIN2+, as determined by follow-up colposcopic inspection with biopsy as indicated) will be determined from medical records (as permitted by HIPAA authorization) and compared between the arms
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Referral to and completion of colposcopy will be determined from medical records (as permitted by HIPAA authorization) and compared between the arms
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Referral to and completion of colposcopy will be determined from medical records (as permitted by HIPAA authorization) and compared between the arms
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Referral to and completion of treatment will be determined from medical records (as permitted by HIPAA authorization) and compared between the arms
Time frame: Throughout data collection period (average of 6 months per participant, approximately 3.5 years of study implementation)
Referral to and completion of treatment will be determined from medical records (as permitted by HIPAA authorization) and compared between the arms
Time frame: 1-5 weeks after completion of self-collection or screening invitation
Attitudes will include multiple components measured by post-intervention questionnaire, including perceived barriers to screening, perceived benefits to screening, defensive processing of risk information, and subjective norms about screening
UNC Lineberger Comprehensive Cancer Center
Other
Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3
Acronym: MBMT-3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05413811
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Westdene, Johannesburg, South Africa
View Trial DetailsNCT01755897
Cervical Cancer, Female Urogenital Diseases
Wuhan, Hubei, China
View Trial DetailsNCT01968837
Cervical Cancer, Female Urogenital Diseases
Moshi, Tanzania
View Trial DetailsNCT00201370
Cervical Cancer, Female Urogenital Diseases
Kaohsiung City, Taiwan
View Trial Details